- SAGE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-3ASR Filing
Sage Therapeutics (SAGE) S-3ASRAutomatic shelf registration
Filed: 5 Jan 16, 12:00am
Exhibit 12.1
Computation of Ratio of Earnings to Fixed Charges
Nine Months Ended September 30, | ||||||||||||||||||
2012 | 2013 | 2014 | 2015 | |||||||||||||||
Net loss attributable to common stockholders(1) | $ | (9,636,393 | ) | $ | (18,288,455 | ) | $ | (36,104,925 | ) | $ | (65,933,323 | ) | ||||||
Fixed charges: | ||||||||||||||||||
Interest expense | — | — | — | — | ||||||||||||||
|
|
|
|
|
|
|
| |||||||||||
Total fixed charges | — | — | — | — | ||||||||||||||
Net loss attributable to common stockholders plus fixed charges | $ | (9,636,393 | ) | $ | (18,288,455 | ) | $ | (36,104,925 | ) | $ | (65,933,323 | ) | ||||||
|
|
|
|
|
|
|
| |||||||||||
Ratio of earnings to fixed charges(2) | N/A | N/A | N/A | N/A |
(1) | The deficiency of earnings available to cover combined fixed charges and preferred dividends includes non-cash deemed dividends to preferred stockholders and accretion of redemption value of redeemable convertible preferred stock of $4,000, $7,000 and $2.3 million for the years ended December 31, 2012, 2013 and 2014, respectively. |
(2) | Due to the Company’s loss for the years ended December 31, 2012, 2013 and 2014 and for the nine months ended September 30, 2015, earnings were insufficient to cover combined fixed charges and preferred dividends by $9,636,393, $18,288,455, $36,104,925 and $65,933,323, respectively. |